viewStarton Therapeutics

ChemioCare advancing 'potentially revolutionary' chemo-induced nausea treatment

ChemioCare CEO Pedro Lichtinger caught up with Proactive's Andrew Scott while in London.

Lichtinger outlines the company's vision which is to transform the current treatment of chemotherapy-induced nausea and vomiting through patch technology.

He says the first patch in their pipeline has completed its development in the lab, it's gone through several tests which prove the blood levels it will deliver in the patient are what they're looking for and they're now working on animals to confirm those blood levels and to check there are no skin irritations or other side effects.

''From there in about 3-4 months we'll go into a proof of concept study in humans ... then in another  3-4 months we'll be in a phase III clinical trial''.

''This will be a small acute trial, you vomit for 5 days, we don't need to follow the patient for a year ...''

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Starton Therapeutics named herein, including the promotion by the Company of Starton Therapeutics in any Content on the Site, the Company...



ChemioCare plans IPO and raise funds to bring 'transformative' drug to the...

ChemioCare CEO Pedro Lichtinger tells Proactive Investors the biopharmaceutical company is focused on treating the side effects of chemotherapy. Founded about a year ago, Lichtinger says the company's transdermal patch technology will help cancer patients going through chemotherapy to...

on 21/5/18

2 min read